{"corpus_id":86816391,"paper_sha":"e1f62ad6f3b78aab54796021d1ab58bc6b78d107","doi":"10.1016/J.ORET.2019.01.018","arxiv_id":null,"pmid":31044729,"pmcid":null,"mag_id":2914844160,"dblp_id":null,"acl_id":null,"title":"Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a \"Treat-and-Extend\" Regimen.","year":2019,"publication_date":"2019-05-01","venue":"Ophthalmology Retina","journal":{"name":"Ophthalmology. Retina","pages":"\n          393-399\n        ","volume":"3 5"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Observational Study"],"s2_fields_of_study":["Medicine"],"reference_count":25,"citation_count":69,"influential_citation_count":2,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Aged, 80 and over","mj":false,"ui":"D000369"},{"d":"Angiogenesis Inhibitors","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D020533"},{"d":"Drug Administration Schedule","mj":false,"ui":"D004334"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Intravitreal Injections","mj":false,"ui":"D058449"},{"d":"Macular Degeneration","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D008268"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Receptors, Vascular Endothelial Growth Factor","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D040262"},{"d":"Recombinant Fusion Proteins","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D011993"},{"d":"Retrospective Studies","mj":false,"ui":"D012189"},{"d":"Visual Acuity","mj":false,"ui":"D014792"}],"chemicals":[{"n":"Angiogenesis Inhibitors","ui":"D020533","reg":"0"},{"n":"Recombinant Fusion Proteins","ui":"D011993","reg":"0"},{"n":"aflibercept","ui":"C533178","reg":"15C2VL427D"},{"n":"Receptors, Vascular Endothelial Growth Factor","ui":"D040262","reg":"EC 2.7.10.1"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"PURPOSE\nTo report outcomes in patients with neovascular age-related macular degeneration (nAMD) after treatment with aflibercept for up to 4 years using a treat-and-extend (T&E) regimen.\n\n\nDESIGN\nObservational study.\n\n\nPARTICIPANTS\nPatients with newly diagnosed nAMD treated with aflibercept in a T&E protocol.\n\n\nMETHODS\nSubjects received 3 injections of aflibercept at monthly intervals followed by a T&E protocol for at least 12 months. At each clinical visit after the loading phase, OCT and best-corrected visual acuity (BCVA) testing were performed to monitor disease activity.\n\n\nMAIN OUTCOME MEASURES\nChange in BCVA over time, number of injections and visits per year, and percentage of patients reaching a treatment interval of ≥12 weeks.\n\n\nRESULTS\nOf 231 consecutive eyes (231 patients) with a mean follow-up time of 2.9 (1-5.5) years, 173 were followed up for ≥2 years, 112 were followed up for ≥3 years, and 62 were followed up for ≥4 years. Mean BCVA increased from 59.8 letters (20/60) at diagnosis to 65.8 letters (20/50) after the loading phase (+6.0 letters; standard deviation [SD], 11.1) and to 65.5 letters at 12 months (+5.7 letters; [SD], 17). After 4 years of treatment, mean BCVA was maintained insignificantly better than baseline (63.4 letters, +3.6 letters gain, SD, 20.6; P > 0.05). To achieve this, a mean of 7.7 (±1.2) injections and 4.4 (±1.6) clinic visits in the first year and 4.4 (±1.9) injections and 4.3 (±1.3) clinical visits per year thereafter were required. By 2 years of follow-up, 46.9% of patients reached a treatment interval of ≥12 weeks.\n\n\nCONCLUSIONS\nBy using a T&E regimen, patients with nAMD maintained stable visual function over 4 years in a real-world setting with a reasonable treatment burden.","claims":[{"public_id":"cl_0b07084d6a0829141c5be483a144bce8","status":"active","text":"A mean of 7.7 (±1.2) injections and 4.4 (±1.6) clinic visits in the first year and 4.4 (±1.9) injections and 4.3 (±1.3) clinical visits per year thereafter were required.","confidence":0.95,"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_0b07084d6a0829141c5be483a144bce8"},{"public_id":"cl_19f9fa8aff08d6851d2280b4238fb9a8","status":"active","text":"After 4 years of treatment, mean BCVA was maintained insignificantly better than baseline (63.4 letters, +3.6 letters gain, SD, 20.6; P > 0.05).","confidence":0.95,"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_19f9fa8aff08d6851d2280b4238fb9a8"},{"public_id":"cl_30f1d3729d4e41b1e9ce387ae52d5b28","status":"active","text":"By 2 years of follow-up, 46.9% of patients reached a treatment interval of ≥12 weeks.","confidence":0.95,"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_30f1d3729d4e41b1e9ce387ae52d5b28"},{"public_id":"cl_24ef2f9c860d05d6c48f58caaf687e08","status":"active","text":"Mean BCVA increased from 59.8 letters (20/60) at diagnosis to 65.8 letters (20/50) after the loading phase (+6.0 letters; SD, 11.1) and to 65.5 letters at 12 months (+5.7 letters; SD, 17).","confidence":0.95,"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_24ef2f9c860d05d6c48f58caaf687e08"}],"concepts":[{"public_id":"co_300a0d2719b5ddf2c7044019f0b7feb9","status":"active","name":"2-year follow-up","description":"Assessment point at 2 years after treatment initiation.","types":["time point"],"aliases":[],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_300a0d2719b5ddf2c7044019f0b7feb9"},{"public_id":"co_49b1c68dc6c57018d359a092b74095a2","status":"active","name":"12-month follow-up","description":"Assessment point at 12 months after treatment initiation.","types":["time point"],"aliases":[],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_49b1c68dc6c57018d359a092b74095a2"},{"public_id":"co_5952458d91591d486fcf699b14d3d722","status":"active","name":"loading phase","description":"Initial three monthly injections of aflibercept before starting the treat-and-extend regimen.","types":["treatment phase"],"aliases":[],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5952458d91591d486fcf699b14d3d722"},{"public_id":"co_5a908a0a3028d8491710105ae4eb5247","status":"active","name":"treatment interval ≥12 weeks","description":"Proportion of patients who achieved a treatment interval of at least 12 weeks between injections.","types":["outcome measure"],"aliases":[],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5a908a0a3028d8491710105ae4eb5247"},{"public_id":"co_a252f3acea26b2cb3e59b98cac812e05","status":"active","name":"injections per year","description":"Mean number of aflibercept injections administered per year during the treat-and-extend regimen.","types":["treatment burden metric"],"aliases":[],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a252f3acea26b2cb3e59b98cac812e05"},{"public_id":"co_b66f4d5f43bd2055ce5c584f16f8a13a","status":"active","name":"clinic visits per year","description":"Mean number of clinical visits per year for monitoring disease activity.","types":["treatment burden metric"],"aliases":[],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b66f4d5f43bd2055ce5c584f16f8a13a"},{"public_id":"co_ea30c649913a60c63818f3652c0af8be","status":"active","name":"best-corrected visual acuity","description":"BCVA measured in letters (Snellen equivalent) used to assess visual function in nAMD patients.","types":["outcome measure"],"aliases":["BCVA"],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ea30c649913a60c63818f3652c0af8be"},{"public_id":"co_f6fe898a2b4efafbc69fc187fb8d5dd6","status":"active","name":"4-year follow-up","description":"Assessment point at 4 years after treatment initiation.","types":["time point"],"aliases":[],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f6fe898a2b4efafbc69fc187fb8d5dd6"}],"external_ids":{"DOI":"10.1016/J.ORET.2019.01.018","ArXiv":null,"PubMed":31044729,"PubMedCentral":null,"MAG":2914844160,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/86816391","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632483,"paper_uid":"9979d537-b550-447e-9c48-df73566e019a","canonical_identity":{"paper_id":632483,"paper_uid":"9979d537-b550-447e-9c48-df73566e019a","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/86816391"}